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conscious sedation or general anesthesia and positive pres-
sure mechanical ventilation using a flexible endotracheal 
tube or a rigid bronchoscope. Chartis and EBV placement 
should be performed in 1 procedure when possible. The se-
quence of valve placement should be orchestrated to avoid 
obstruction and delivery of subsequent valves. If atelectasis 
has not occurred by 1 month after procedure, evaluate valve 
position on CT and consider replacing the valves that are not 
optimally positioned. Pneumothorax is a common complica-
tion and typically occurs in the first 2 days following treat-
ment. A management algorithm for pneumothorax has 
been previously published. Long-term sequelae from EBV 
therapy do occur but are easily manageable. 
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Endoscopic lung volume reduction (ELVR) is being 
adopted as a treatment option for carefully selected pa-
tients suffering from severe emphysema. The Zephyr en-
dobronchial valve (EBV; Pulmonx Corp., Redwood City, 
 Keywords 
 Bronchoscopic lung volume reduction · Chronic obstructive 
pulmonary disease · Collateral ventilation · Emphysema · 
Endobronchial valves · Hyperinflation · Bronchoscopy 
 Abstract 
 Endoscopic lung volume reduction (ELVR) is being adopted 
as a treatment option for carefully selected patients suffer-
ing from severe emphysema. ELVR with the one-way endo-
bronchial Zephyr valves (EBV) has been demonstrated to im-
prove pulmonary function, exercise capacity, and quality of 
life in patients with both heterogeneous and homogenous 
emphysema without collateral ventilation. In this “expert 
best practices” review, we will highlight the practical aspects 
of this therapy. Key selection criteria for ELVR are hyperinfla-
tion with a residual volume >175% of predicted, forced ex-
piratory volume <50% of predicted, and a 6-min walking dis-
tance >100 m. Patients with repeated infectious complica-
tions, severe bronchiectasis, and those with unstable 
cardiovascular comorbidities should be excluded from EBV 
treatment. The procedure may be performed with either 
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CA, USA) is an implantable device designed to occlude 
bronchi in diseased regions of the lung and to allow for the 
expiration of air from the treated lobe of the lung. When 
placed correctly and in appropriate patients, EBV reduces 
hyperinflation which manifests in clinical improvement 
 [1] . The effectiveness of EBV is dependent on the absence 
of collateral ventilation between the lobe with valves and 
the ipsilateral lobe. The Chartis Diagnostic System (Pul-
monx) enables accurate and precise assessment of collat-
eral ventilation status  [2] . Used together, the Chartis Di-
agnostic System and Zephyr EBVs have been demonstrat-
ed to provide meaningful benefits of improved pulmonary 
function, exercise capacity and quality of life in patients 
with both heterogeneous  [3] and homogenous emphyse-
ma  [4] .  Table 1 provides an overview of the most relevant 
EBVs for emphysema trials in the field.
 Based on the extensive experience of the panel mem-
bers from many of the most experienced centers in Eu-
rope, this monograph discusses practical and effective ap-
proaches to optimizing patient outcomes, including pa-
tient selection, patient preparation, patient management, 
and postoperative care and follow-up.
 Patient Selection 
 As with every medical procedure, patient selection re-
mains an integral part of the successful outcomes. Impor-
tant selection criteria include:
 Spirometry and Hyperinflation 
 There are no absolute spirometry cutoffs when consid-
ering patients for EBV treatment. In clinical practice and 
clinical trials, however, most patients have a postbron-
chodilator forced expiratory volume in 1 s (FEV 1 ) below 
50% of predicted  [1, 5] , including some patients with 
FEV 1 values as low as 15% of predicted. More important-
ly, because ELVR is thought to work primarily by reduc-
ing lung hyperinflation, it is imperative to select patients 
for EBV therapy that have hyperinflated lungs ( Fig. 1 ). 
Consistent with previous trials and expert recommenda-
tions, patients should display evidence of hyperinflation 
as measured by a TLC >100% and RV >175%, both mea-
sured by body plethysmography  [1, 6] .
 Collateral Ventilation 
 The absence of collateral ventilation between the treat-
ed and ipsilateral lobes is critical for procedural success. 
The Chartis System is the most studied diagnostic tool for 
identifying potential responders to EBV treatment based 
on the absence of collateral ventilation in the target lobe 
 [2] . Because of the considerable interoperator variability 
of determining lobar fissure integrity by visual assess-




ΔRV (L) (treatment 
vs. control) 
p value ΔFEV1% 
(treatment vs. 
control) 
p value Δ6MWT, m
(treatment 
– control)
p value ΔSGRQ, points 
(treatment – 
control)
p value Pneumothorax 
rate, % of total 
treated
IMPACT [4] (3) –0.48 (–0.84, –0.11) 0.011 17.0 (8.1, 25.8) <0.001 40 (15, 65) 0.002 –9.64 (–14.1, –5.2) <0.001 25.6
STELVIO [9] (6) –0.83a (–1.10, –0.56) <0.001 17.8 (7.6, 28) 0.001 74 (47, 100) <0.001 –14.7a (–21.8, –7.6) <0.001 18.0
BELIEVER [3] (3) –0.37 (–0.72, –0.03) 0.079 20.9 (4.3, 37.5) 0.033 33 (–3, 69) 0.012 –5.1 (–14.4, 4.3) 0.345 8.0
VENTb [11] (6) –0.46 0.022 24.8 <0.001 28 0.065 –8.4 (–13.8, –3.0) 0.003 11.4c
 Figures in parentheses indicate 95% CI. FEV1, forced expiratory volume in 1 s; RV, residual volume; 6MWD, 6-min walk distance; SGRQ, Saint George’s 
Respiratory Questionnaire total score. a Completed cases data. b Subgroup analysis on subjects with complete fissures (n = 61 in both groups) and lobar 
occlusion (n = 61 in EBV treatment group). c Includes 3 subjects with “ex-vacuo” (stable) pneumothorax.
 Fig. 1. X-ray of a typical EBV candidate. Note hyperinflation and 



















   
   
   
   
   
   
   
   
   


























ment on high-resolution computed tomography (HRCT) 
scans, this approach is not generally recommended as a 
means of ruling patients in or out for EBV treatment. 
Quantitative CT analysis has shown early promise, with 
predictive capabilities in the same range as Chartis in 
small data sets  [7] . More recent data  [8] support the use 
of quantitative CT measurements to screen in patients for 
further analysis and/or treatment with fissure complete-
ness  ≥ 80%. Patients with fissure integrity <80% are not 
considered for EBV treatment. If quantitative CT analysis 
shows fissure completeness between 80 and 95%, per-
forming an additional Chartis measurement to confirm 
absence of collateral flow is very important to avoid non-
responders to the treatment. If the fissure completeness 
is >95%, EBV treatment can be directly performed, with 
Chartis being optional. A typical quantitative CT recon-
struction of fissure completeness is displayed in  Figure 2 .
 Exercise Capacity 
 Patients should have some level of preserved exercise 
capacity in order to tolerate the procedure and poten-
tial complications. Patients with a 6-min walk distance 
(6MWD) between 100 and 500 m should be considered 
for EBV treatment). In patients with a 6MWD below
200 m, reassessment should be considered after pulmo-
nary rehabilitation.
 Emphysema Morphology 
 A low-dose thin-slice (0.5–1.5 mm) volumetric HRCT 
scan should be used to evaluate the degree and distribu-
tion of emphysema. Though most clinical research and 
experience to date has been focused on the benefit of EBV 
treatment in patients with heterogeneous emphysema, 
recent findings suggest that EBV benefits patients with 
homogeneous emphysema  [9] and thus, emphysema het-
erogeneity should no longer be considered an exclusion 
criterion for this therapy  [4, 9] . Coronal, sagittal, and ax-
ial reconstructions of HRCT scans can help determine 
which lobes have greater destruction for purposes of 
choosing a primary – and if applicable – secondary target 
lobe. In patients with a more homogeneous disease dis-
tribution, a perfusion scan should be performed to pro-
vide additional information to select the appropriate tar-
get lobe that should exhibit low perfusion compared with 
the ipsilateral untreated lobe  [10] .
 The physician should carefully review the CT scan for 
findings, such as bulla in or adjacent to the target lobe 
(which may suggest the need for additional vigilance after 
procedure for a pneumothorax), pathologies or nodules 
(requiring further assessment and/or follow-up), infiltra-
tions or cavity (suggesting active infection, which should 
be treated before procedure), or disqualifying criteria 
(such as severe bronchiectasis, severe paraseptal emphy-
sema, extensive fibrosis or other conditions that may sig-
nificantly impair outcomes; see  Fig. 3 ).
 Prior Surgery 
 For patients who have had previous pulmonary surger-
ies, a key consideration is whether the target lobe is on the 
same side of the lung as the previous surgery or the con-
tralateral lung. Patients who have had bullectomies, lobar, 
segmental-, or wedge resections on the contralateral lung 
may still be considered candidates if they meet the other 
screening criteria. Patients with prior surgery on the same 
side as the target lobe (including bilateral lung transplant 
or previous bilateral LVRS), or patients with previous 
pleurodesis should be excluded for safety reasons due to 
possible lack of compliance in the remaining lobes.
 Hypercapnia 
 Patients with severe hypercapnia (>60 mm Hg on 
room air) and/or severe hypoxemia (<45 mm Hg on room 
air) should be excluded from EBV treatment  [11, 12] . 
However, in patients that display evidence of hypercap-
nia, reassessment after a trial of at least 3 months of regu-
lar noninvasive ventilation may be warranted.
 Medical History and Stability 
 Available clinical data have shown that EBV treatment 
benefits patients that are α 1 -antitrypsin deficient  [13] , have 
 Fig. 2. Quantitative CT reconstruction with fissure rendering il-
lustrating a complete major fissure of left lung, a nearly complete 
major fissure of the right lung (>95%), and an incomplete minor 
fissure (<80%). Numbers indicate percent of fissure completeness 
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homogeneous distribution of emphysema  [4, 9] , have up-
per or lower lobe predominant emphysema  [14] , and have 
pulmonary hypertension  [1, 15] . Patients with unstable 
cardiovascular disease such as severe heart failure (left ven-
tricular ejection fraction <35% despite optimal medical 
management), unstable cardiac arrhythmia, myocardial 
infarction, or stroke within the past 6 months should be 
excluded until stabilized or improved. Although not an ab-
solute contraindication, patients with pulmonary hyper-
tension with RVSP >45 mm Hg (using echocardiography 
or right heart catheter measurement) should be treated 
with caution. Patients that are clinically unstable despite 
optimal medical management with more than 3 exacerba-
tions resulting in hospitalizations in the previous 12 months 
are excluded until further stabilized. ELVR should not be 
performed in patients with significant symptomatic bron-
chiectasis and chronic sputum production with microbio-
logical colonization, such as pseudomonas or MRSA.
 Overall, any one single criterion should not automati-
cally disqualify a candidate if other measures appear fa-
vorable, and physicians should exercise caution and 
sound clinical judgment in selecting appropriate candi-
dates. 
 Thus, patients for EBV treatment should be selected 
based on the following minimal criteria:
 • Residual volume >175% predicted 
 • FEV 1 between 15 and 50% of predicted 
 • No evidence of significant coexistent pulmonary pa-
thology on HRCT 
 • Little or no collateral ventilation in the targeted lobe 
for treatment 
 • Clinically stable prior to the procedure 
 • Able to safely undergo sedation or general anesthesia 
and bronchoscopy 
 • Cessation of smoking 
 Key Messages 
 • Residual volume and collateral ventilation are the 
most important inclusion criteria; patients with em-
physema and RV >175% predicted should be evaluat-
ed for collateral ventilation 
 • Patients with either homogeneous or heterogeneous 
emphysema who are able to tolerate the procedure and 
any potential complications should be considered can-
didates for valve treatment 



















   
   
   
   
   
   
   
   
   


























 Bronchoscopy and the Chartis Procedure 
 Both the Chartis procedure and subsequent placement 
of the EBVs in patients without collateral ventilation neg-
ative (CV–) are performed during a bronchoscopy. Once 
the patient is ready to undergo the bronchoscopy, there 
are a number of important nuances that can make the 
procedure easier. It is important that the patient is ade-
quately medicated to provide anxiolysis, analgesia, and 
topical anesthesia to ensure patient comfort and mini-
mize movement. The approach to patient preparation 
and management is outlined below.
 Patient Management 
 General Anesthesia 
 This is the preferred and recommended method both 
for the Chartis measurement and the subsequent valve 
placement due to the ease of airway and patient manage-
ment. Positive pressure ventilation minimizes distortion 
to the Chartis measurements  [8] particularly with low 
ventilation frequency (8–10×/min) and long expiratory 
settings (I/E ratio 1: 3–1: 4).
 Where applicable, depending on the sedation ap-
proach used, it is also often useful to apply topical lido-
caine (1–2%) in the airways, particularly in the lobar 
bronchus of the target lobe prior to performing the Char-
tis assessment.
 Sedation 
 It is critically important to achieve or maintain an op-
timal level of sedation. Individual Institutional sedation 
guidelines should be followed. Optimal sedation during 
the Chartis procedure is critical, as the patient must ex-
hibit enough tidal breathing in order to validate the de-
tection of a CV-negative target, but must be adequately 
sedated to avoid coughing and/or secretion production. 
An important consideration is that with increasing seda-
tion, a majority of these patients can develop respiratory 
failure and increased carbon dioxide retention. Thus, 
moderate sedation is ideal, and deep sedation should be 
considered at facilities with appropriate support and re-
covery resources. The choice of medications for good pa-
tient management is typically determined by physician 
preference as well as country or institution-specific 
guidelines and practices. The most common approach 
for sedation is using a combination of a short-acting ben-
zodiazepine and a narcotic, which can be easily titrated 
and readily reversed. Typical combinations for sedation 
include:
 • Propofol + (remi-)fentanyl sedation, and topical lido-
caine 
 • Midazolam + fentanyl + topical lidocaine 
 Secretion Management 
 Secretions can be adequately managed with minimal 
amounts of saline and suction to enhance visibility and 
device placement. However, excessive suctioning or im-
precise scope control can lead to airway edema, mucosal 
bleeding and inflammation, which can adversely affect 
valve sizing decisions. The use of antisialogogue agents 
such as glycopyrrolate or atropine to blunt the produc-
tion of airway secretions can be considered. Use of either 
of these drying agents should follow institutional guide-
lines, and physician’s caution should be exercised due to 
their chronotropic risks.
 The Chartis Procedure 
 The introduction of the Chartis balloon catheter into 
the bronchoscope is helped by application of a lubricating 
gel to the front end of the catheter. When the balloon is 
inserted into the bronchoscope, the obturator should be 
retained within the balloon catheter to prevent the cath-
eter from kinking and prevent secretions from entering 
the airflow channel. It is recommended that the balloon 
and bronchoscope are positioned outside of the ostium of 
the target lobe with the black marker of the balloon cath-
eter visible prior to balloon inflation. Inflate the balloon 
just in front of the ostium, then use the bronchoscope to 
maneuver the balloon into place to initiate contact with 
the ostium. Carefully inspect the positioning of the cath-
eter to ensure that there is adequate contact between the 
balloon and the airway wall. An adequate seal is indicated 
by circumferential blanching of the mucosa. Once veri-
fied, the bronchoscope should be gently advanced over 
the Chartis catheter and rested against the balloon to al-
low visualization thru the balloon and ensure that the dis-
tal end of the catheter is not being obstructed by secre-
tions, the airway wall, or septum ( Fig. 4 ).
 When using conscious sedation and once the stylet is 
removed, regular flow should be seen on the Chartis dis-
play prior to initiating the assessment. Be prepared to per-
form the assessment for up to 6 min, assuming there is 
good balloon contact. Care should be taken to closely 
monitor for catheter obstruction, as obstruction can 
cause an immediate drop of the flow curve and substan-
tially extend the measurement. Once the flow is visualized 
and measured, the trend is typically quite evident. How-
ever, it can take some time to remove the volume of air 
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ing a downward trend in the flow reading. Therefore, it is 
important to consider the volume of exhaled air (which is 
displayed on the Chartis console) in addition to the time 
of assessment in order to conclude definitive collateral 
ventilation status of the target lobe. It is recommended 
that the operator observes both a significant volume of air 
recorded (800–1,000 mL) and a reasonable assessment 
time of at least 5–6 min to conclude a positive assessment 
of collateral ventilation ( Fig. 5 ). Of note, the Chartis mea-
surement is on average shorter when performed under 
general anesthesia.
 Fig. 4. Correct Chartis balloon catheter placement to occlude the right lower lobe (RLL) airway by inflating the 
balloon and placing it onto the ostium. Note the circumferential blanching of the bronchial wall, indicating the 
balloon seal and correct position of the catheter tip. ML, middle lobe. 
 Fig. 5. Chartis system output screen demonstrating assessment time and volume of exhaled air from the target 



















   
   
   
   
   
   
   
   
   


























 These parameters will help prevent a false CV-positive 
assessment. The slope of the flow decrement curve de-
pends on the compliance and pressure of the lobe being 
measured; however, the decrease should be steady if the 
lobe is CV negative. The validity of measurement can be 
confirmed by continuing the measurement after stop-
ping the assessment without deflating or moving the bal-
loon; a notable spike in the expiratory flow once the as-
sessment is stopped, confirms that the measurement was 
correct.
 Occasionally, despite the best technique, testing for 
collateral ventilation can be inconclusive. For these situ-
ations, the ipsilateral lobe can be evaluated as a surrogate 
for CV negativity in the target lobe. This is straightfor-
ward for the left lower lobe, because there is only 1 fissure. 
To indirectly measure the right lower lobe, plug the right 
middle lobe (consider using a regular balloon catheter or 
Watanabe spigot) and use the Chartis balloon in the right 
upper lobe.
 CV status is confirmed by a gradual decrease and even-
tual cessation of expiratory airway flow in addition to a 
corresponding increase in resistance. This will appear
differently depending on the ventilation method used 
( Fig. 6 )  [16, 17] .
 Balloon Placement for Right Lower Lobe Assessment 
 Due to the anatomy of the airway in the right lower 
lobe, ensure the balloon is inflated at the level of the B6 
segment, blocking airflow into the segment but maintain-
ing a patent right middle lobe for correct assessment 
( Fig. 7 ).
 An important consideration that may affect patient 
outcome is the effect of oxygen saturations during the as-
sessment procedure: If it decreases significantly during 
assessment, abort and avoid treating that lobe, as it may 
indicate wrong assessment or important contribution of 
the lobe to total V/Q [Slebos, pers. commun.]. Proceed to 
assess a secondary target lobe if available.
 Key Messages 
 • Using general anesthesia with conventional mechani-
cal positive pressure ventilation is the recommended 
approach to perform the Chartis assessment and valve 
placement; both Chartis assessment and valve place-
ment can be successfully performed under conscious 
sedation also, but this method is technically more chal-
lenging 
 • Perform Chartis and EBV placement in 1 procedure 
where possible (2 procedures may increase the risk of 
bronchoscopy induced exacerbations) 
a b c
 Fig. 6. Chartis procedure showing absence of collateral flow performed under different anesthetic methods.  a Positive pressure ventila-
tion.  b Conscious sedation.  c Jet ventilation. 
 Fig. 7. Chartis balloon placement occluding the RB6 segment in 
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 • If Chartis measurements are inconclusive even after 
evaluating the ipsilateral (nontarget) lobe or the sec-
ondary target lobe, there are 2 options: 
 – Study CT scan for fissure completeness; retrospective 
data suggest a high proportion of patients with fissure 
completeness above 80% may be responders  [3] ; this 
may be further supported if the trend for Chartis sug-
gests no significant collateral ventilation 
 – Alternatively, repeat the Chartis assessment after con-
verting the patient to general anesthesia with positive 
pressure ventilation 
 EBV Placement 
 Before placing the valves ( Fig.  8 ), a clear treatment 
plan should be developed, starting with the selection of 
the target lobe and then considering the anatomy of the 
airways leading to that lobe. If possible, identify a second-
ary target based on the distribution of disease and/or per-
fusion and negative collateral ventilation status.
 The target lobe should be selected combining absence 
of collateral ventilation, greater emphysema tissue de-
struction on CT, and confirmation of low lobar perfusion 
using perfusion scintigraphy. Also in patients where mul-
tiple target lobes are identified, perfusion scintigraphy, 
especially in homogeneous emphysema, may be helpful 
to identify the target lobe (low perfusion in the target, 
with high perfusion in the ipsilateral, not to be treated 
lobe) ( Fig. 9 )  [17, 18–20] . Furthermore, absence of large 
bulla adjacent to the target lobe, paraseptal emphysema, 
as well as absence of severe scarring, fibrotic lesions, and 
significant pleural adhesions is critical.
 Efficient placement of the valves requires careful air-
way evaluation and systematic and thoughtful placement. 
It is important to review the patient’s CT scan prior to the 
procedure to evaluate the airway anatomy and consider 
the depth and size of each target segment. This will help 
define the order of valve placement and prevent overlap 
of the proximal ends of the valves, which can sometimes 
obstruct access to subsequent airways where valves are to 
be placed. Consideration should therefore be given to first 
placing the valves in the more distal and least accessible 
a b c
 Fig. 8. Currently available sizes of Zephyr ® 
endobrochial valves (EBV, Pulmonx) de-
signed to occlude varying bronchial airway 
lengths, with diameters between 4.0 and
8.5 mm.  a EBV-TS-4.0-LP.  b EBV-TS-4.0. 
 c EBV-TS-5.5. 
a b
 Fig. 9. An HRCT scan with homogeneous 
emphysema distribution ( a ) with an ac-
companying perfusion scintigraphy scan 
indicating areas of lower perfusion espe-



















   
   
   
   
   
   
   
   
   


























airways, prior to the easier more accessible proximal air-
ways. The depth marker on the endobronchial delivery 
catheter can be used to help determine the distance that 
the valve will protrude from the landing zone and validate 
the optimal order of placement. It is very important to 
ensure the target segment has enough length between the 
distal bifurcating carina and ostium to land the body of 
the valve. This can be accomplished by ensuring the 
length of the airway segment is greater than the distance 
from the tip of the delivery catheter to the blue marker 
( Fig. 10 ). This distance represents the length of the valve 
housing that should be seated behind the ostium to en-
sure correct placement.
 In addition, the wings on the catheter should be used 
to identify the minimum and maximum diameter of the 
valve ( Fig. 11 ). The longer wings, representing the maxi-
mum diameter of the valve, should touch the airway walls 
at the widest point of the lumen. This can be accom-
plished by rotating the catheter by turning the handle 
when the catheter is in position. The 2 shorter wings in-
dicate the smallest size of the bronchial segment that can 
be treated. When in doubt, physicians should oversize the 
diameter of the valve if they have the airway depth to do 
so, as this will provide a tighter seal.
 During the placement of a valve, it can be helpful to 
locate the tip of the delivery catheter just outside of the 
bronchoscope and then maneuver as close as possible to 
the target area. After valve sizing measurements are made, 
advance the catheter so that the marker on the tip of the 
catheter is visible and then slowly, partially release the 
valve proximal to the bifurcating carina ( Fig. 12 ). The en-
tire unit should be then advanced to the carina and then 
fully deployed; this ensures the valve blocks all airways 
distal to the target bronchus, i.e. that the valve is not in-
advertently deployed down a subsegmental airway. Note 
that during valve deployment, the catheter will automati-
 Fig. 10. EBV 4.0 EDC delivery catheter 
with depth markers illustrating the appro-
priate length of the valve body for the EBV-
TS-4.0-LP (thin blue line) and EBV-TS-4.0 
valves (thick blue line). 
 Fig. 11. EBV delivery catheter width sizing 
wings used to determine the minimum and 
maximum diameter of the valve. 
 10  11 
 Fig. 12. Partial deployment technique illus-
trating EBV placed directly onto the next 
distal carina. 
 Fig. 13. The EBV delivery catheter with a 
depth marker distal to the ostium ensuring 
valve housing sits within the target seg-
mental airway. 



















   
   
   
   
   
   
   
   
   





















 Endobronchial Valves: “How to Do It” Respiration 2017;93:138–150
DOI: 10.1159/000453588
147
cally retract into the bronchoscope. Accidental or manu-
al retraction of the delivery catheter during valve deploy-
ment is a common cause of valve misplacement.
 If there is a longer segment where placement of valves 
directly on the distal carina is not easily achievable, posi-
tion the depth marker on the delivery catheter slightly 
distal (1–2 mm) to the ostium of the target segment and 
deploy the valve ( Fig. 13 ). It is important to note that a 
valve should never be deployed before visualizing the lo-
cation of the distal carina to ensure the valve is correctly 
positioned to block all the airways of the target segment.
 It is often tempting to place a single 5.5 valve in the 
lower lobes for the basal pyramid; however, this can often 
result in valve movement (possible dislodgement or loss 
of volume reduction). Instead, multiple valves should be 
used at the next bifurcation. In airway targets where the 
valve protector region is in contact with the proximal air-
way, irritation and/or formation of granulation tissue 
could occur  [9, 11] . Therefore, shorter valves or deeper 
placement may be optimal. The “low profile” EBV-TS-
4.0-LP valve is often useful for placement in short seg-
ments.
 After valve placement, chest X-ray evaluation is rec-
ommended immediately and again after 4 h. Bed rest and 
cough suppression can be helpful for patient comfort. 
Significant volume reduction or atelectasis of the treated 
lobe may be observed within the first few days, although 
in some patients it may take up to a month. If there is no 
visible volume reduction on X-ray at 1 month, the Panel 
recommends performing a low dose CT scan to study 
valve positioning and consider replacing any valve(s) that 
do not appear to be correctly positioned relative to the 
anatomy, which may result in a leak into the target lobe 
( Fig. 14 ).
 Key Messages 
 • The sequence of valve placement should be in an order 
so that they do not obstruct the deployment of subse-
quent valves 
 • Always ensure a distal bifurcating carina is visualized 
prior to deploying the valve to ensure the valve is de-
ployed proximal to the carina 
 • When in doubt, oversize the valves and treat lower 
lobes more distally 
 • If atelectasis has not occurred by 1 month after treat-
ment in a lobe that has been confirmed as CV negative, 
evaluate valve position on CT and consider replacing 
the incorrectly positioned valves 
 Management of Acute Complications 
 The most common complications of EBV placement 
include pneumothorax, pneumonia, respiratory exacer-
bations, and valve migrations  [2, 11, 21] .  All of these re-
quire immediate attention, and the medical staff should 
be instructed to anticipate, recognize and treat these com-
plications. The currently available data suggest that the 
pneumothorax rate is approximately 20–30% in experi-
enced centers  [9] . Because this is relatively common, we 
recommend vigilance to proactively detect and treat these 
events. Skilled and aggressive pneumothorax manage-
ment is warranted in this patient population as every 
pneumothorax, in particular a tension pneumothorax, 
can be life threatening. A management algorithm for 
pneumothorax has been previously published  [22] and 
should be adhered to. There are not a lot of published data 
regarding the time of occurrence of pneumothorax after 
treatment. Approximately 80% of pneumothoraces occur 
in the first 48 h, 10% within days 3–5, and 10% after day 
6  [23] . Hence, current practice is to admit patients to hos-
pital for 3–5 days following insertion of EBV. Maintain 
an emergency pneumothorax kit at the patient’s bedside 
for rapid decompression.
 Patients that demonstrate significant volume reduc-
tion on postprocedure chest X-rays may present a higher 
 Fig. 14. Axial reconstruction of a CT image demonstrating poor 




















   
   
   
   
   
   
   
   
   


























risk of pneumothorax due to movement in the pleural 
cavity and should be closely monitored. Patients and staff 
should be educated on the signs and symptoms of pneu-
mothorax, and patients’ discharge instructions should in-
clude clear steps to take if pneumothorax symptoms oc-
cur.
 After valve placement, up to 20% of patients can man-
ifest acute bronchitis, pneumonia and/or lung infections 
within the first 3 months of the procedure  [11, 21] . Acute 
bronchitis often occurs following routine bronchoscopy 
and is independent of valve placement  [24] . To decrease 
the incidence of bronchitis and respiratory exacerbations, 
many centers prescribe prophylactic antibiotics and a 
short course of oral steroids. If a bacterial pneumonia oc-
curs, we suggest prescription of a broad spectrum oral 
antibiotic initially. If pneumonia does not clear with ini-
tial course of antibiotic, we suggest removal of valves and 
prescription of a second course of IV or oral antibiotics. 
We would then consider replacing valves 6 weeks after the 
pneumonia has cleared.
 Valve migration is rare, but should be suspected when 
a patient experiences increased coughing or sudden per-
ceived loss of efficacy. A chest X-ray should be performed 
to exclude a pneumothorax. If this is unremarkable, we 
recommend conducting a CT scan and/or bronchoscopy 
to inspect for valve migration and misplacement. During 
the bronchoscopy, the displaced valve should be removed 
and replaced immediately. Valve migration predomi-
nantly occurs if the initial valve has been seated incor-
rectly or undersized.
 COPD exacerbations are expected but rarely seen dur-
ing hospitalization as activity is limited. If they occur, 
standard treatment with bronchodilators, antibiotics, 
and corticosteroid are recommended. The GOLD guide-
lines outline this management extensively  [25] .
 Key Messages 
 • Pneumothorax is a common complication (20% of 
cases) and typically occurs in the 2 days following 
treatment, but can occur after discharge 
 • Signs of significant volume reduction on postproce-
dure chest X-rays may indicate a higher risk of pneu-
mothorax; patients should be closely monitored 
 • Patients and staff should be trained to recognize symp-
toms of pneumothorax 
 • A management algorithm for pneumothorax has been 
previously published and should be adhered to 
 • Infections, pneumonia, and COPD exacerbations 
should be treated according to standard of care 
 Long-Term Follow-Up and Management of 
Complications 
 Long-term complications do occur after EBV place-
ment; however, the overall risk to benefit ratio favors the 
use of EBV therapy  [26–28] . In most cases, the complica-
tions can be managed by the patient’s primary pulmo-
nologist, but coordinated and collaborative communica-
tion between the primary pulmonologist and treating 
center is essential and strongly recommended. The most 
common long-term complications include pneumonia, 
COPD exacerbations, granulation tissue formation and 
valve migrations/loss of efficacy  [11, 21, 29] . Because the 
patient will often be back under the care of their primary 
physician, in order to ensure a smooth transition back to 
their care, it is critical to keep the patient’s referring team 
apprised of the planned procedure, outcomes, and poten-
tial complications.
 We recommend following up with the patient’s refer-
ring physician at 1, 3, and 6 months, and yearly after the 
procedure to maintain surveillance of all patient out-
comes and possible complications. The patient and fam-
ily should be sufficiently informed and must understand 
when to alert their treating physician. A 24-h hotline is 
also recommended so that patients can contact an on call 
provider if questions or emergencies arise.
 In the long term, we re-evaluate patients if there is a 
loss of effect, no effect, or other complications. If the pa-
tient’s breathing deteriorates or there is no improvement, 
we recommend an additional low-dose CT scan to assess 
valve positioning as appropriate. If the patient has any of 
the following, we recommend the addition of broncho-
scopic evaluation and valve adjustment or replacement:
 • No volume reduction (at scheduled 30–45-day check, 
or symptom triggering study) on CT scan 
 • Sudden loss of benefit/loss of volume reduction on CT 
 • Persistent cough 
 • Persistent hemoptysis 
 • Obstruction pneumonia 
 • Pneumothorax management 
 If the patient is having an increased frequency of respi-
ratory exacerbations, but no changes are seen on the CT 
scan, we will first assess exacerbation frequency prior to 
EBV treatment to determine if this is the likely natural 
course of the disease or due to valves. If it is the natural 
course of the disease, then we would recommend that the 
primary pulmonologist consider increasing doses of in-
haled bronchodilators and other therapies as outlined in 
the GOLD guidelines. If the patient has had a loss of ef-
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to evaluate for abnormalities such as migration or granu-
lation tissue formation. Granulation tissue formation has 
been noted in some cases  [9, 11] and can present asymp-
tomatically, or with persistent cough, hemoptysis or loss 
of volume reduction after initial success.
 Sometimes, it may not be due to the direct interaction 
of the valve with the target bronchus itself but due to an 
interaction of the valve housing with the adjacent bron-
chial wall or if an edge of an eccentrically placed valve 
scratches over the mucosa during a cough. In either case, 
the management is to remove the valve and if needed ad-
dress any granulation tissue with cryoablation if available. 
Replace the valve either with one more distally positioned 
or with a larger-sized valve 6 weeks later, assuming gran-
ulation tissue has disappeared (depending on bronchus). 
Care must be taken to place the valve as centrally as pos-
sible to avoid wall irritation.
 Airway remodeling or bronchial torsion has been ob-
served on rare occasions  [9] . A tightly fitted valve may 
leak if the bronchus reshapes elliptically. Changing the 
valve is recommended in such a situation.
 Long-term infection is rare, and the recommendation 
is to follow the standard course of 7–14 days of oral anti-
biotics. If pneumonia does not clear after appropriate an-
tibiotic therapy, consider removing the valves and pre-
scribing a 2nd course of antibiotic therapy.
 Key Messages 
 • Long-term sequelae from EBV treatment do occur but 
are generally manageable 
 • Ongoing communication between the patient’s physi-
cian and treating physician is important to evaluate 
symptoms and decide next steps together 
 • A repeat bronchoscopy may be necessary to restore 
loss of initial benefit due to valve dislocation, expecto-
ration, or granulation tissue formation 
 Conclusion 
 EBV treatment for emphysema is an efficacious ther-
apy that is proven to improve lung function, exercise ca-
pacity, and quality of life in patients afflicted with emphy-
sema and absence of collateral ventilation in the target 
lobe. These clinical best practice recommendations 
should aid physicians in maximizing the response rate 
and patient outcomes with EBV treatment.
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